Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Dierig

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Biometrical Journal. Biometrische Zeitschrift|January 27, 2015
A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessmentRichard Nixon, Christoph Dierig, Shahrul Mt-Isa, et al.
Circulation|November 23, 2006
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacementBengt I Eriksson, Lars C Borris, Ola E Dahl, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Biometrical Journal. Biometrische Zeitschrift|January 27, 2015
A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessmentRichard Nixon, Christoph Dierig, Shahrul Mt-Isa, et al.
Circulation|November 23, 2006
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacementBengt I Eriksson, Lars C Borris, Ola E Dahl, et al.
Pageof 1